Cargando…

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

BACKGROUND: Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration, signaling and apoptosis induction in preclinical models of non-V600 BRAF muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molnár, Eszter, Rittler, Dominika, Baranyi, Marcell, Grusch, Michael, Berger, Walter, Döme, Balázs, Tóvári, József, Aigner, Clemens, Tímár, József, Garay, Tamás, Hegedűs, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941622/ https://www.ncbi.nlm.nih.gov/pubmed/29739364 http://dx.doi.org/10.1186/s12885-018-4455-x

Ejemplares similares

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
por: Rittler, Dominika, et al.
Publicado: (2020)

The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb
por: Rittler, Dominika, et al.
Publicado: (2019)

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression
por: Molnár, Eszter, et al.
Publicado: (2019)

Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation
por: Hegedüs, Luca, et al.
Publicado: (2021)

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
por: Garay, Tamás, et al.
Publicado: (2015)

BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition
por: Obasaju, Patience, et al.
Publicado: (2020)

Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca(2+) Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK
por: Hegedüs, Luca, et al.
Publicado: (2017)

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models
por: Kenessey, István, et al.
Publicado: (2016)

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
por: Tóvári, József, et al.
Publicado: (2023)

HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
por: Hegedűs, Luca, et al.
Publicado: (2020)

Apelin promotes lymphangiogenesis and lymph node metastasis
por: Berta, Judit, et al.
Publicado: (2014)

Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells
por: Tátrai, Enikő, et al.
Publicado: (2017)

K-Ras prenylation as a potential anticancer target
por: Baranyi, Marcell, et al.
Publicado: (2020)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Role of retinoic receptors in lung carcinogenesis
por: Bogos, Krisztina, et al.
Publicado: (2008)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma
por: Rózsás, Anita, et al.
Publicado: (2013)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b
por: Naffa, Randa, et al.
Publicado: (2020)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition
por: Allen, Amy, et al.
Publicado: (2019)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
por: Radeczky, Peter, et al.
Publicado: (2021)

Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma
por: Busch, Elena, et al.
Publicado: (2020)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line
por: Stockhammer, Paul, et al.
Publicado: (2021)

Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
por: Fusco, Michael J., et al.
Publicado: (2021)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial
por: Tian, Jun, et al.
Publicado: (2023)

Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
por: Toll, Stephanie A., et al.
Publicado: (2019)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
por: Munjapara, Vasu, et al.
Publicado: (2022)

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity
por: Gadiot, Jules, et al.
Publicado: (2013)

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fhersiqbsfusi8j7a2kla5tqnu